ImmuCell Corporation

ImmuCell reported higher second-quarter sales and earnings as domestic demand for its calf scours prevention products increased, while outlining plans to invest about $8 million to more than triple manufacturing capacity by the end of 2027. Product sales rose 11.5% year over year to $7.2 million in the second quarter of 2026, and net income increased to $1.8 million, or $0.20 per share, from $500,000, or $0.06 per share, a year earlier. Domestic sales grew 27.7% to $6.2 million, offsetting a 38.9% decline in international sales to about $1 million. The company said First Defense's share of U.S. animals treated with biological scours preventatives rose to about 19% by June from 15% in December 2025. Gross margin fell to 33.9% from 43.7% a year earlier, pressured by lower production output, scrap costs, and recurring expenses tied to the discontinued Re-Tain program.

Several biotech stocks reached 52-week highs on July 10, 2026, driven by regulatory updates and quarterly results. American Well Corporation hit $10.16, closing at $9.91, after a Nature report validated its SilverCloud platform and it facilitated a DarioHealth insurer agreement, though full-year 2026 revenue is expected at $195 million to $205 million, below 2025's $249.3 million. Cue Biopharma reached $45.50 and announced a roughly $50 million private placement, while advancing CUE-221 in a Phase 2 allergy study and planning an IND for CUE-401. ImmuCell climbed to $11.59 after reporting unaudited second-quarter sales of $7.2 million, an 11.5% year-over-year increase, with $4.9 million from Tri-Shield First Defense. Scholar Rock hit $58.49, up 3.33%, as its BLA for Apitegromab in SMA is under FDA review with a decision expected by September 30, 2026. Faeth Therapeutics touched $36.89, advancing the PIKTOR combination therapy in a Phase 1/2 breast cancer trial with interim data due in 2027 and a Phase 2 endometrial cancer trial with topline data expected in the second half of 2026.

ImmuCell Corporation reported preliminary second-quarter total product sales of $7.2 million, an 11.55% increase from $6.4 million a year earlier, driven by its TriShield First Defense product. Domestic sales rose 27.7% to $6.2 million, while international sales fell 38.9% to $1 million. TriShield First Defense, used to prevent scours in newborn calves, generated $4.9 million in product sales, up 8.3% from $4.5 million in the prior-year quarter. For the six months ended June 30, 2026, total product sales climbed 20.9% to $17.5 million from $14.5 million in the same period last year.

Zacks Equity Research released new research reports on 16 major stocks, including JPMorgan Chase, Novartis, and Qualcomm, along with micro-cap companies Genie Energy and ImmuCell. JPMorgan's consumer franchise continues to expand with U.S. branch builds and planned Chase digital expansion in Europe, though elevated expenses and a tough macro backdrop raise asset quality concerns. Novartis faces a challenging 2026 due to the largest patent cliff in its history from Entresto generic competition, but its strong portfolio including Kisqali and Pluvicto supports mid-term growth. Qualcomm is pivoting toward a broader connected processor portfolio with solid automotive traction, yet handset demand uncertainty and increasing in-house chip development by OEMs could pressure market share. Genie Energy, a microcap with a market capitalization of $386.24 million, is repositioning its renewables platform toward owned-generation assets while managing margin pressure from commodity volatility. ImmuCell, a microcap with a market capitalization of $88.57 million, continues to gain market share in calf scours prevention through manufacturing improvements and a focus on its First Defense product line.